Skip to main content
    U

    Unicycive Therapeutics Inc (UNCY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.59
    -0.11 (-2.97%)

    Market Cap: $102.18M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(9/21)
    Avg Surprise
    -12.52%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.35
    Range$-0.66 - $-0.23
    9 analysts
    EPS Revisions
    1
    0
    7d
    3
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.36+3.5%
    60d ago$-0.36+3.5%
    30d ago$-0.35+0.3%
    7d ago$-0.35+0.3%
    Current$-0.35
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.11
    Range$-0.46 - $0.53
    9 analysts
    Revenue Consensus
    $1M
    Range$0 - $10M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.11---
    Sep 26EST
    		-$-0.35---
    Jun 26
    Reported Aug 12
    		$-0.06N/A+82.35%Beat+88.5%
    Mar 26
    Reported May 12
    		$-0.54$-0.48-11.47%Miss-7.3%
    Dec 25
    Reported Mar 30
    		$-0.82$-0.46-78.26%Miss-428.0%
    Sep 25
    Reported Nov 12
    		$-0.33$-0.53+37.74%Beat+34.0%
    Jun 25
    Reported Aug 14
    		$-0.52$-0.70+25.71%Beat-134.7%
    Mar 25
    Reported May 14
    		$-0.50$-0.62+19.35%Beat+91.8%
    Dec 24
    Reported Mar 27
    		$0.25$-0.09+373.52%Beat+213.6%
    Sep 24
    Reported Nov 12
    		$-0.50N/A+67.11%Beat+61.5%
    Jun 24
    Reported Aug 14
    		$1.50$-1.92+178.13%Beat+151.7%
    Mar 24
    Reported May 13
    		$-6.10$-1.55-293.55%Miss+37.1%
    Dec 23
    Reported Mar 28
    		$-0.22$-0.17-29.41%Miss+37.1%
    Sep 23
    Reported Nov 14
    		$-1.30$-1.30+0.00%Beat+64.9%
    Jun 23
    Reported Aug 14
    		$-2.90$-3.20+9.38%Beat-20.8%
    Mar 23
    Reported May 16
    		$-9.70$-3.72-160.75%Miss-304.2%
    Dec 22
    Reported Mar 31
    		$-0.35$-0.24-45.83%Miss-45.8%
    Sep 22
    Reported Nov 14
    		$-3.70$-2.80-32.14%Miss+0.0%
    Jun 22
    Reported Aug 15
    		$-2.40$-2.27-5.73%Miss-84.6%
    Mar 22
    Reported May 12
    		$-2.40$-1.90-26.32%Miss-3328.6%
    Dec 21
    Reported Mar 31
    		$-0.24$-0.13-84.62%Miss-300.0%
    Sep 21
    Reported Nov 11
    		$-3.70$-1.00-270.00%Miss-12233.3%
    Jun 21
    Reported Aug 16
    		$-1.30$-1.10-18.18%Miss-
    Mar 21
    Reported May 21
    		$-0.07$0.00N/AMiss-
    Sep 20
    Reported Nov 2
    		$-0.06$0.00N/AMiss-
    Jun 20
    Reported Sep 15
    		$-0.03$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.06EV/EBITDAN/A
    Price/FCF-3.47xFCF Yield-28.82%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-101.10%ROIC-54.29%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio3.81xQuick Ratio3.81x
    Trading Statistics
    Beta1.82Avg Volume937.15K
    52-Week High$8.7452-Week Low$3.59

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.01
    SMA 20$4.37
    SMA 50$4.89
    SMA 200$6.22
    EMA 10$4.00
    EMA 20$4.28
    EMA 50$4.80
    EMA 200$5.72

    MACD

    Line: -0.35Signal: -0.28Hist: -0.06

    ADX

    ADX: 35.6+DI: 8.3-DI: 37.3

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$4.01

    Bollinger Bands

    Upper Band$5.20
    Lower Band$3.54
    %B Position3797%(Upper)
    Band Width0.03

    RSI (14-Day)

    Oversold
    21.9

    Momentum Oscillators

    Stoch %K5.4
    Stoch %D6.2
    Williams %R-97.6
    ROC (10d)-21.1%
    Momentum-0.96
    CCI (20d)-145.0
    MFI (14d)15.4

    Volatility Measures

    ATR (14d)$0.23(6.3%)
    StdDev (20d)0.41
    Hist Vol45.5%(High)

    Volume Flow

    VWAP$3.62
    OBV-38.6M
    AD Line20.5B
    CMF (20d)-0.157

    Volume Metrics

    Avg Vol (20d)953.1K
    Vol Ratio0.9x
    VWMA (20d)$4.31

    Pivot Points

    R3$4.03
    R2$3.92
    R1$3.81
    Pivot Point$3.70
    S1$3.59
    S2$3.48
    S3$3.37

    Advanced Oscillators

    TSI-41.88
    Ultimate Osc36.4
    KST-202.73

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$568,000$0$0$0$-271,000$0
    Cost of Revenue$0$0$151,000$0$0$0$284,000$0$0$0$82,000$0
    Gross Profit$0$0$-151,000$0$0$0$284,000$0$0$0$-353,000$0
    Operating Expenses$10.14M$8.44M$7.22M$7.34M$6.96M$7.99M$9.26M$6.25M$7.40M$9.20M$6.31M$5.94M
    R&D$2.79M$1.61M$2.24M$2.96M$1.75M$2.17M$5.29M$3.04M$4.87M$6.81M$4.23M$3.37M
    SG&A$7.35M$6.83M$4.99M$4.38M$5.21M$5.82M$3.97M$3.21M$2.53M$2.39M$2.08M$2.57M
    Operating Income$-10,140,000$-8,437,000$-7,223,000$-7,342,000$-6,963,000$-7,989,000$-9,261,000$-6,251,000$-7,401,000$-9,204,000$-6,312,000$-5,938,000
    Interest Income$441,000$394,000$352,000$279,000$155,000$226,000$314,000$416,000$462,000$69,000$140,000$227,000
    Interest Expense$0$0$28,000$15,000$13,000$15,000$20,000$15,000$16,000$20,000$20,000$18,000
    Income Before Tax$-1,722,000$-12,823,000$-14,667,000$-6,011,000$-6,447,000$570,000$-21,525,000$-4,096,000$9.86M$-20,963,000$-7,798,000$-4,333,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,722,000$-12,823,000$-14,667,000$-6,011,000$-6,447,000$570,000$-21,525,000$-4,096,000$9.86M$-20,963,000$-7,798,000$-4,333,000
    EBITDA$-2,045,000$-12,994,000$-14,840,000$-6,265,000$-6,451,000$494,000$-21,812,000$-4,491,000$9.30M$-20,728,000$-7,915,000$-4,540,000
    EBIT$-2,163,000$-13,217,000$-14,991,000$-6,275,000$-6,589,000$359,000$-21,819,000$-4,497,000$9.41M$-21,012,000$-7,918,000$-4,542,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about UNCY

    News

    SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY

    SueWallSt is reminding investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) about a securities class action lawsuit with a lead plaintiff deadline of November 2...

    PR Newswire•10/15/26•Bearish

    Unicycive Therapeutics, Inc. Class Action Reminder -

    Robbins LLP reminds investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) about a class action lawsuit filed against the company. The lawsuit alleges that Unicycive failed to disclose issues with its third-party...

    GlobeNewswire•10/14/26•Bearish

    Deadline Alert: Unicycive Therapeutics, Inc. (UNCY)

    Glancy Prongay Wolke & Rotter LLP is urging investors of Unicycive Therapeutics, Inc. (UNCY) who suffered losses to contact them regarding a securities fraud lawsuit. The lawsuit stems from a significant drop...

    GlobeNewswire•10/14/26•Bearish

    Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY

    Levi & Korsinsky, LLP has filed a class action lawsuit against Unicycive Therapeutics, Inc. on behalf of investors who purchased securities between December 29, 2025, and June 29...

    PR Newswire•10/14/26•Bearish

    Unicycive resubmits NDA and HC Wainwright targets Unicycive Therapeutics stock

    Unicycive Therapeutics has resubmitted its New Drug Application (NDA) for oxylanthanum carbonate, including 12 months of stability data from a new manufacturing vendor. The FDA is expected to accept the application...

    ad-hoc-news.de•10/14/26•Bullish

    UNCY Valuation and Fair Value

    P/E
    -2.1x
    Forward P/E
    1.5x
    P/FCF
    -3.5x
    P/B
    1.8x
    See GNG's fair value

    UNCY Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -54.3%
    ROE
    -101.1%
    FCF yield
    -28.8%

    UNCY Competitors

    CompanyTicker
    PDS Biotechnology CorpPDSB
    Inovio Pharmaceuticals IncINO
    Armata Pharmaceuticals IncARMP
    Corbus Pharmaceuticals HoldingCRBP
    Vivani Medical Inc.VANI
    Humacyte IncHUMA
    Definitive Healthcare CorpDH
    The Joint CorpJYNT

    Sector: Healthcare

    UNCY Analyst Ratings

    Consensus
    Buy
    Analysts
    10
    Strong Buy
    2
    Buy
    8
    Hold
    0
    Sell
    0
    Strong Sell
    0

    UNCY Bull Case vs Bear Case

    Bull case

    • UNCY beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of UNCY's analyst ratings are Buy or Strong Buy.

    UNCY Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    64.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.35
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 2 down

    Frequently Asked Questions About UNCY

    Does UNCY pay dividends?

    Unicycive Therapeutics Inc (UNCY) does not currently pay a regular dividend.

    What is UNCY's market cap?

    Unicycive Therapeutics Inc (UNCY) has a market capitalization of $102.18M with a current stock price of $3.59.

    Related stocks

    Sector: Healthcare

    All stocks starting with U

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In